Multiple myeloma in association with second malignancy

被引:0
作者
Grudeva-Popova, J. [1 ]
Nenova, I. [1 ]
Spasova, M. [2 ]
Yaneva, M. [3 ]
Beleva, E. [1 ]
Ananoshtev, N. [4 ]
机构
[1] Univ Multiprofile Hosp Act Treatment Sv Georgi, Dept Oncol & Hematol, Plovdiv, Bulgaria
[2] Univ Multiprofile Hosp Act Treatment Sv Georgi, Dept Pediat & Med Genet, Plovdiv, Bulgaria
[3] Univ Multiprofile Hosp Act Treatment Sv Georgi, Dept Radiotherapy, Plovdiv, Bulgaria
[4] Comprehens Oncol Hosp, Plovdiv, Bulgaria
来源
JOURNAL OF BUON | 2013年 / 18卷 / 02期
关键词
multiple myeloma; risk factors; second malignancy; survival; CHRONIC LYMPHOCYTIC-LEUKEMIA; CANCER; RADIOTHERAPY; SURVIVAL; RISK;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To look at the frequency of second primary malignancies (SECMAL) in patients with multiple myeloma (MM). Methods: The medical files of 332 patients with MM (whole group), diagnosed and treated at the University Multiprofile Hospital for Active Treatment "Sv. Georgi" and the Comprehensive Oncology Hospital "Plovdiv" for a 20-year period (1990-2010) were retrospectively analyzed. MM patients with SECMAL constituted the study group. A control group comprised patients with solid tumors associated with SECMAL This group derived from a sample of 21768 patients with solid tumors. Results: In the study group, SECMAL was diagnosed in 152% (N=15) of the patients, while in the control group this figure was 5.09% (N=1108) (p>0.05). The diagnosis of MM preceded the occurrence of SECMAL in 35.71% of the study group patients, the median interval being 6.6 years (range 5-14). More frequently the diagnosis of the solid tumor preceded the occurrence of MM (66.67%). Breast cancer and gastric cancer were encountered with the highest frequency (26.67% each). The median survival (77.2 months, range 44-129) was significantly longer in the group with MM and SECMAL compared to the whole group with MM (median 38.6 months, range 10-58; p <0.05). Conclusion: The rate of MM with other malignant diseases is comparable with the frequency of SECMAL in other lymphoproliferative disorders and solid tumors. The occurrence of SECMAL during the clinical course of MM is not a frequent event and is expected in the rare cases with longer survival.
引用
收藏
页码:448 / 452
页数:5
相关论文
共 21 条
  • [1] [Anonymous], 2008, CONCISE MANUAL HEMAT, P599
  • [2] Arslan C, 2011, J BUON, V16, P744
  • [3] Chakraborty S, 2012, ANTICANCER RES, V32, P4507
  • [4] Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
    Cheson, BD
    Vena, DA
    Barrett, J
    Freidlin, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2454 - 2460
  • [5] Dasanu C, 2010, LEUKEMIA RES, V34, P178
  • [6] A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Brandenburg, Nancy
    Yu, Zhinuan
    Weber, Donna M.
    Niesvizky, Ruben
    Morgan, Gareth J.
    [J]. BLOOD, 2012, 119 (12) : 2764 - 2767
  • [7] Giles FJ, 1998, SEMIN ONCOL, V25, P117
  • [8] Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood
    Haddy, Nadia
    Le Deley, Marie Cecile
    Samand, Akhtar
    Diallo, Ibrahima
    Guerin, Sylvie
    Guibout, Catherine
    Oberlin, Odile
    Hawkins, Mike
    Zucker, Jean-Michel
    de Vathaire, Florent
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) : 2757 - 2764
  • [9] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [10] Ovarian Carcinosarcomas Associated With Prolonged Use of Tamoxifen Case Reports
    Lavie, Ofer
    Longacre, Teri
    Segev, Yakir
    Husain, Amreen
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (09) : 1521 - 1523